Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 1
2003 1
2004 2
2006 3
2007 2
2008 3
2009 4
2010 3
2011 1
2012 1
2013 2
2014 3
2015 3
2018 3
2019 6
2020 5
2021 3
2022 3
2023 3
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Guttman-Yassky E, et al. Among authors: tenorio ar. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. Lancet. 2021. PMID: 34023008 Clinical Trial.
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Simpson EL, et al. Among authors: tenorio ar. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029. JAMA Dermatol. 2022. PMID: 35262646 Free PMC article.
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Cahn P, et al. Among authors: tenorio ar. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Lancet. 2019. PMID: 30420123 Clinical Trial.
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Cahn P, et al. Among authors: tenorio ar. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.
Fostemsavir resistance in clinical context: a narrative review.
Schapiro JM, Kaiser R, Krystal M, Parry CM, Tenorio AR, Stewart E, Gilliam B, Gartland M, Clark A, Castillo-Mancilla JR. Schapiro JM, et al. Among authors: tenorio ar. Ther Adv Infect Dis. 2025 Mar 24;12:20499361251325103. doi: 10.1177/20499361251325103. eCollection 2025 Jan-Dec. Ther Adv Infect Dis. 2025. PMID: 40145022 Free PMC article. Review.
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Aberg JA, Shepherd B, Wang M, Madruga JV, Mendo Urbina F, Katlama C, Schrader S, Eron JJ, Kumar PN, Sprinz E, Gartland M, Chabria S, Clark A, Pierce A, Lataillade M, Tenorio AR. Aberg JA, et al. Among authors: tenorio ar. Infect Dis Ther. 2023 Sep;12(9):2321-2335. doi: 10.1007/s40121-023-00870-6. Epub 2023 Sep 26. Infect Dis Ther. 2023. PMID: 37751019 Free PMC article.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Guttman-Yassky E, Thyssen JP, Silverberg JI, Papp KA, Paller AS, Weidinger S, Chih-Ho Hong H, Hendrickson B, Dilley D, Tenorio AR, Ladizinski B, Chu AD, Liu J, Irvine AD. Guttman-Yassky E, et al. Among authors: tenorio ar. J Allergy Clin Immunol. 2023 Jan;151(1):172-181. doi: 10.1016/j.jaci.2022.09.023. Epub 2022 Oct 1. J Allergy Clin Immunol. 2023. PMID: 36195170 Free article.
52 results